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SUMMARY
Knowledge of hepatitis B and C prevalence, and numbers infected, are important for planning
responses. Published HBsAg and anti-HCV prevalences for the 20 WHO European Region
countries outside the EU/EFTA were extracted, to complement published data for the
EU/EFTA. The general population prevalence of HBsAg (median 3·8%, mean 5·0%, seven
countries) ranged from 1·3% (Ukraine) to 13% (Uzbekistan), and anti-HCV (median 2·3%, mean
3·8%, 10 countries) from 0·5% (Serbia, Tajikistan) to 13% (Uzbekistan). People who inject drugs
had the highest prevalence of both infections (HBsAg: median 6·8%, mean 8·2%, 13 countries;
anti-HCV: median 46%, mean 46%, 17 countries), and prevalence was also elevated in men who
have sex with men and sex workers. Simple estimates indicated 13·3 million (1·8%) adults have
HBsAg and 15·0 million (2·0%) HCV RNA in the WHO European Region; prevalences were
higher outside the EU/EFTA countries. Efforts to prevent, diagnose, and treat these infections
need to be maintained and improved.
This article may not be reprinted or reused in any way in order to promote any commercial
products or services.
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INTRODUCTION
Infection with the hepatitis B and C viruses (HBV and
HCV) causes signiﬁcant morbidity and mortality.
Even though HBV infection can be prevented through
vaccination, the World Health Organization (WHO)
has estimated that globally around 240 million people
are chronically infected [1, 2] with between 500000 and
700000 deaths each year [1, 3]. WHO estimates also
indicate that 2–3% of the world’s population are
HCV-infected, equating to 120–170 million people
[4]. About 1·0 million people die annually (∼2·7%
of all deaths) from causes related to viral hepatitis,
most commonly liver disease, including liver cancer
[5]. An estimated 57% of liver cirrhosis cases and
78% of primary liver cancers result from HBV or
HCV infection [6]. Co-infections with HIV are an
increasing problem in countries with HIV epidemics
in people who inject drugs (PWID), and in those
treated with HIV anti-retrovirals, and underlying
viral hepatitis is becoming a major cause of death [5].
Globally there are geographical variations in the
extent of both HBV and HCV infection including
within Europe [4]. In the European Union (EU) and
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European Free Trade Association (EFTA) area,
prevalence in the general population varies from
0·4% to 5·2% for anti-HCV and from 0·1% to 5·6%
for HBsAg [7]. Hepatitis prevalence in the rest of the
WHO European Region, mainly eastern Europe and
central Asia countries, has not been assessed even
though this part of the Region has recently experi-
enced an accelerating HIV epidemic and an increase
in the population of PWID [8].
HBVandHCVare bloodborne viruses that are easily
transmitted through blood-to-blood contact [2, 9–11].
Parenteral routes, particularly injecting drug use or
poor hygiene in clinical settings, are major sources of
transmission [2, 9–12]. HBV can also be transmitted
sexually, and this route has also been reported for
HCV in certain circumstances [10, 13]. Perinatal trans-
mission of bothHBVandHCV can also occur [2, 9, 10].
The majority of adults infected with HBV spon-
taneously resolve their infection and develop protective
immunity [11]. Less commonly chronic infection results
and, in rare cases, causes potentially fatal acute liver
failure [11]. In contrast to HBV, the majority of
HCV-infected adults develop chronic disease [14].
Those with chronic infections remain infectious to
others and are at risk of developing serious liver disease
such as cirrhosis or hepatocellular cancer [15, 16]. The
available antiviral treatments for both HBV and
HCV infections have increased and becomemore effec-
tive [17, 18]. Treatment may also have a role in preven-
tion through reducing the pool of infectious people [19].
As chronic HBV and HCV infections are largely
asymptomatic, many patients who might beneﬁt
from treatment remain undetected [20]. Efforts are
needed to detect those infected and who would
beneﬁt from treatment, so that the costly sequelae
of infection can be reduced [21, 22]. To target case-
ﬁnding it is necessary to know which population
groups are most affected; and information on the
likely numbers infected is needed for healthcare plan-
ning, for example, to assess the cost of providing treat-
ment. Examination of these at a regional level allows
comparison of the burden between countries as well as
informing international responses.
The aims of this study were to: (a) assess the pre-
valence of HBV and HCV infection in the WHO
European Region countries outside the EU/EFTA
through a literature review; (b) generate simple esti-
mates of the numbers living with HBV and HCV
infection in these countries, and (c) to compare this
burden with that in the rest of the WHO European
Region obtained from published data [7].
MATERIALS AND METHODS
Literature review
Studies that had measured HBV and HCV seropre-
valence since 2000 were identiﬁed through a literature
review. To be included, studies had to: (a) have tested
a biological sample (self-reports were excluded) to
measure prevalence of HBsAg or anti-HCV in a
WHO European Region country outside the EU/
EFTA area (n=20, Table 1); (b) do so in one or
more of these adult population groups: general popu-
lation, blood donors, pregnant women, PWID, men
who have sex with men (MSM), and sex workers;
and (c) have been published from 2000 to 2010 inclus-
ive. Studies not meeting these criteria or reporting
sample sizes <100 were excluded.
Medline and EMBASE were searched for studies
on the prevalence of HBV and HCV (see Sup-
plementary online material for search terms). The
grey literature were indentiﬁed through searches of
documents held by the WHO Regional Ofﬁce for
Europe, the European Monitoring Centre for Drugs
and Drug Addition (EMCDDA) website, and the
sources identiﬁed in a systematic review on HIV in
the WHO European Region – which had system-
atically collected data on seroprevalence studies (in-
cluding those with a focus on viral hepatitis) [8].
Bibliographies were checked for further sources. The
titles and abstracts were ﬁrst reviewed to identify
relevant publication (in English or Russian), the full
text was then assessed for inclusion and data extracted
(including secondary reports). Data relating to screen-
ing of ﬁrst-time blood donors was obtained from the
Council of Europe report [23].
The prevalences in pregnant women were combined
with the general population data. The nature of this
population, women of child-bearing age, could mean
that the prevalence might not reﬂect that overall in
the general population, particularly if prevalence dif-
fers by gender or age, or if fertility rates are higher
in migrant groups with higher prevalences; however,
we have assumed that such differences are likely to
be small overall. Prevalence in ﬁrst-time blood donors
was not combined with the general population data,
as blood donors are a highly select group. In most
countries those who may have been at risk of infection
with bloodborne viruses are excluded from giving
blood, thus blood donors are usually likely to be at
lower risk overall than the general population.
A ‘selected prevalence’ estimate in the general
population was obtained for each country using the
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Table 1. Number and geographical coverage of studies that had measured the prevalence of hepatitis B surface antigen (HBsAg) or antibodies to the hepatitis C
virus (anti-HCV) in each population group by country: countries in the WHO European Region outside EU/EFTA
(a) General population and blood donors
Country
General population Blood donors
HBsAg Anti-HCV HBsAg Anti-HCV
No. of
studies
Coverage
of studies
No. of
studies
Coverage
of studies
No. of
studies
Coverage
of studies
No. of
studies
Coverage
of studies
Albania 3 National (x2),
1 city/area
1 1 city/area 2 1 city/area, n.s. 2 1 city/area, n.s.
Armenia 0 0 0 0
Azerbaijan 0 0 0 0
Belarus 0 0 0 0
Bosnia & Herzegovina 0 0 1 National 2 National,
1 city/area
Croatia 0 0 1 National 1 National
Georgia 0 1 1 city/area 0 0
Israel 0 0 1 National 1 National
Kazakhstan 1 1 city/area 2 National,
1 city/area
1 National 0
Kyrgyzstan 0 1 2 cities/areas 0 0
Montenegro 0 0 1 National 1 National
Republic of Moldova 0 0 0 0
Russian Federation 2 ?National,
1 city/area
2 ?National,
1 city/area
1 1 city/area 1 1 city/area
Serbia (incl. Kosovo*) 1 1 city/area 1 1 city/area 1 1 city/area 1 1 city/area
Tajikistan 0 1 Multi-site 1 National 1 National
The former Yugoslav
Republic of Macedonia
0 0 1 1 city/area 1 1 city/area
Turkey 9 Multi-site (x2),
1 city/area (x7)
7 Multi-site,
1 city/area (x6)
3 National,
1 city/area (x2)
3 National,
1 city/area (x2)
Turkmenistan 0 0 0 0
Ukraine 4 Unclear 3 Unclear 3 Unclear 2 Unclear
Uzbekistan 1 Multisite 1 Multisite 1 Multisite 2 Multisite
Total 21 20 18 18
2
7
2
V
.D
.
H
o
p
e
a
n
d
o
th
ers
Table 1 (cont.)
(b) People who injecting drugs (PWID)
PWID
HBsAg Anti-HCV
No. of
studies
Coverage
of studies
No. of
studies Coverage of studies
Albania 1 1 city/area 2 1 city/area
Armenia 0 0
Azerbaijan 1 Multi-site 2 Multi-site, 2 cities/areas
Belarus 1 Multi-site 2 Multi-site, 1 city/area
Bosnia & Herzegovina 2 Multi-site 2 Multi-site
Croatia 3 National multi-site,
1 city/area
3 National, multi-site, 1 city/area
Georgia 3 1 city/area 4 Multi-site, 1 city/area (x3)
Israel 1 National 1 National
Kazakhstan 1 2 cities/areas 2 National, 2 cities/areas
Kyrgyzstan 0 2 Multi-site, 2 cities/areas
Montenegro 1 Unclear 2 1 city/area, unclear
Republic of Moldova 1 National 1 National
Russian Federation 2 2 cities/areas, 1 city/area 16 Multi-site (x2), 1 city/area (x12), unclear (x2)
Serbia (incl. Kosovo*) 1 1 city/area 3 Multi-site, 1 city/area (x2)
Tajikistan 0 2 Multi-site, 1 city/area
The former Yugoslav Republic
of Macedonia
0 0
Turkey 1 Multi-site 1 1 city/area
Turkmenistan 0 0
Ukraine 3 1 city/area (x1),
unclear (x2)
6 1 city/area (x4), unclear (x2)
Uzbekistan 0 2 National multi-site
Total 22 53
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Table 1 (cont.)
(c) Men who have sex with men (MSM) and sex workers
MSM Sex workers
HBsAg Anti-HCV HBsAg Anti-HCV
No. of
studies
Coverage
of studies
No. of
studies
Coverage
of studies
No. of
studies
Coverage
of studies
No. of
studies
Coverage
of studies
Albania 1 1 city/area 0 0 0
Armenia 0 0 0 0
Azerbaijan 1 1 city/area 1 1 city/area 1 Multi-site 1 Multi-site
Belarus 0 0 0 0
Bosnia & Herzegovina 1 National 1 National 1 National 1 National
Croatia 1 1 city/area 2 1 city/area, national 0 1 National
Georgia 1 1 city/area 1 1 city/area 0 0
Israel 0 0 0 0
Kazakhstan 0 1 National 0 1 National
Kyrgyzstan 0 1 National 0 3 National multi-site,
1 city/area
Montenegro 0 0 0 0
Republic of Moldova 0 1 1 city/area 0 1 1 city/area
Russian Federation 0 1 2 cities/areas 0 3 Multi-site,
1 city/area (x2)
Serbia (incl. Kosovo*) 1 1 city/area 1 1 city/area 1 1 city/area 1 1 city/area
Tajikistan 0 0 0 1 National
The former Yugoslav Republic
of Macedonia
0 0 0 0
Turkey 1 Multi-site 0 2 Multi-site,
1 city/area
1 1 city/area
Turkmenistan 0 0 0 0
Ukraine 1 Unclear 1 Unclear 1 Unclear 1 Unclear
Uzbekistan 0 0 0 2 Multi-site,
1 city/area
Total 8 11 6 17
EU/EFTA, European Union and European Free Trade Association area; n.s., not stated.; ‘?’, preceding a detail indicates that the information available on this item in the
source was limited.
* According to United Nations Security Council Resolution 1244 (1999).
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algorithm in Table 2. This was applied to other groups
if sufﬁcient studies were identiﬁed.
Simple estimates of number infected
The total number of adults currently infected with
HBV and HCV was estimated by applying the
HBsAg and anti-HCV prevalences to the 2008
national adult (aged 515 years) population estimates
[24]. In countries that had a selected prevalence in
blood donors only, the prevalence in the general popu-
lation was simply imputed from the blood-donor data.
This was done by using the median ratio of the blood-
donor estimates to the general population estimates
for those countries with selected estimates for both
of these groups. For countries with no general popu-
lation and no blood-donor estimate the median of
the selected general population’s prevalences was
used. Medians were used as the distributions were
skewed, with a small number of countries having a
much higher prevalence than the rest; the median
thus gives a more conservative estimate than would
be obtained using the mean. For HCV, 74% of those
anti-HCV positive were assumed to have current
infection [25].
To obtain comparable simple estimates of the num-
bers living with these infections in the EU/EFTA
countries the same method was applied to published
data (n=30, excluding four with populations
<100000). Prevalence in ﬁrst time blood donors was
taken from the Council of Europe report [23], with
additional data from an European Centre for
Disease Prevention and Control (ECDC) review [7]
(HBsAg prevalence for 27 countries, anti-HCV for
26). General population prevalences were obtained
from the ECDC review, this had obtained selected
prevalences for the EU/EFTA countries using a simi-
lar method (13 countries HBsAg, 12 anti-HCV) [7].
The numbers of current PWID infected with HBV
and HCV were obtained by applying the selected
PWID HBsAg and anti-HCV prevalences to pub-
lished national estimates of the number of current
injectors [26, 27]. Where national estimates of the cur-
rent injecting population were not available the
median of the national prevalences of injecting drug
use was used to impute the number of PWID from
the adult population data. For countries with no
HBsAg or anti-HCV prevalence estimate for PWID
the median of the selected national prevalences was
used. Medians were again used as the distributions
were skewed. As with the general population for
HCV, 74% of those anti-HCV positive were assumed
to have current infection [25].
To obtain comparable simple estimates of the
number of PWID living with these infections in the
EU/EFTA countries prevalence data from studies
undertaken since 1999 was downloaded from the
EMCDDA website [27] (all EU states and Norway
report HBV and HCV seroprevalences for PWID to
EMCDDA) and literature searches for Switzerland
and Iceland (not members of EMCDDA). Selected
prevalence estimates were then derived using the
same algorithm as above. Numbers were then esti-
mated using the same approach, including impu-
tations for missing data, as for the countries outside
EU/EFTA.
RESULTS
After accounting for studies reported by more than
one publication, a total 86 sources were identiﬁed
(Supplementary Fig. S1).
Prevalence: general population and blood donors
Twenty-one studies, undertaken in seven countries
(35% of total), had measured HBsAg prevalence in a
group representing the general population (Table 1):
11 recruited from the general population, ﬁve preg-
nant women, and ﬁve other groups (Supplementary
Table S1). Half of these studies had recruited from one
city/area (Table 1). Thirteen countries (65%) had
measured HBsAg prevalence in blood donors
(18 studies, 39% had national coverage, Table 1).
Together the general population and blood donor
studies covered 13 countries. The study HBsAg prev-
alences ranged from 0·1% (blood donors, Bosnia &
Herzegovina) to 13% (general population, Uzbekistan,
Supplementary Table S1). The selected country
Table 2. Algorithm used to select a national
prevalence
Prevalences were selected using the following hierarchy:
(1) National studies.
(2) Studies with multiple sites across the country.
(3) Regional/city levels studies.
If more there was than one study (for example several
multi-site studies) then the weight mean was used
(or mean if this could not be calculated) to obtain
the selected prevalence.
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HBsAg prevalence estimates (Table 3, Fig. 1) ranged
from 1·3% to 13% for the general population (median
3·4%, mean 5·0%) and from 0·1% to 8·4% for blood
donors (median 1·1%, mean 2·2%). The selected gen-
eral population prevalence was higher than the
selected blood-donor prevalence in ﬁve of the seven
countries with both (Table 3), the median of the ratio
between these was 1·4 (range 0·57–2·6, mean 1·6).
Ten countries (50%) had measured the anti-HCV
prevalence in groups representing the general popu-
lation (20 studies: nine recruited from the general popu-
lation, six pregnant women, ﬁve other groups), with
two-thirds of these studies covering one city/area
(Table 1). Twelve countries (60%) had measured
anti-HCV prevalence in blood donors (18 studies,
39% recruited from one city/area, Table 1). Together
these measures covered 15 countries (75%). The study
anti-HCV prevalences ranged from 0·03% (blood
donors, Bosnia & Herzegovina) to 13% (general popu-
lation, Uzbekistan, Supplementary Table S1). The
selected country estimates (Table 3, Fig. 1) ranged
from 0·5% to 13% for the general population (median
2·3%, mean 4·3%) and from 0·03% to 6·4% for blood
donors (median 0·46%, mean 1·3%). The selected gen-
eral population prevalence was higher than the selected
blood-donor prevalence in six of the seven countries
with measures of both (Table 3), the median of the
ratio between these was 2·1 (range 0·17–9·2, mean 3·0).
Prevalence: PWID
Fourteen (70%) countries had measuredHBsAg preva-
lence and 17 (85%) anti-HCV prevalence in PWID
(Table 1). In total 54 studies were identiﬁed, including
30 that had recruited from community settings; eight
from needle and syringe programmes, low-threshold
facilities, harm reduction, or outreach services; three
from addiction treatment settings; four through other
service types; and ﬁve through mixed settings (setting
was unclear in four, see Supplementary Table S2).
The mean sample size was 650 (range 60–4860, median
319). Twenty-two studies had measured HBsAg
(38% recruited in one city/area, Table 1) and 53 studies
anti-HCV prevalence (53% recruited in one city/area,
Table 1). The study HBsAg prevalences ranged from
0% to 34%, and the anti-HCV prevalences from 5·3%
to 95% (Supplementary Table S2). The selected
country prevalence estimates (Table 4, Fig. 1) ranged
from 0·8% to 31% for HBsAg (median 6·8%, mean
9·2%) and from 5·3% to 73% for anti-HCV (median
46%, mean 46%).
Prevalence: MSM
Thirteen studies were found that had measured the
prevalence of either HBsAg or anti-HCV in MSM
(Supplementary Table S3). The samples sizes ranged
from 61–741 (mean 235, median 157), and the
majority had recruited MSM from community set-
tings (11, 85%). Eight (40%) countries had undertaken
a single study that had measured the HBsAg preva-
lence in MSM (ﬁve recruited from one city/area,
Table 1). The prevalences ranged from 0% to 18%
(Supplementary Table S3) with a median of 6·4%
(mean 6·9%). Eleven studies (from 10 countries,
50%) reported anti-HCV prevalence in MSM (ﬁve
recruited from one city/area, Table 1). The median
of study anti-HCV prevalence was 4·2% (mean
7·8%, range 0–16%, Supplementary Table S3).
Prevalence: sex workers
Seventeen studies (Supplementary Table S4) had
measured the prevalence of either HBsAg or anti-
HCV in sex workers: samples sizes ranged from
138–2249 (mean 591, median 315). Almost half of the
studies (eight, 47%) recruited sex workers from com-
munity settings, with four recruiting through services
(23%) and two (12%) from both community settings
and services (setting unclear for three, Supplementary
Table S4). Six studies, from ﬁve countries (25%),
reported an HBsAg prevalence in sex workers (two
recruited from one city/area, Table 1); prevalence
ranged from 2% to 18% (Supplementary Table S4),
the median was 2·9% (mean 6·1%). Seventeen studies
from 12 countries (60%), reported an anti-HCV preva-
lence in sexworkers (seven recruited from one city/area,
Table 1); prevalences ranged from2·4% to 40% (median
11%, mean 14%).
Imputation of general population prevalence from
blood donors
General population prevalence estimates were im-
puted from the blood-donor prevalence using the
median ratio of the general population to the blood-
donor prevalence derived from those countries with
both (Table 3). Applying this ratio to the blood-
donor prevalence in those countries from which
it was derived, gave a median difference between
the countries measured and the imputed general popu-
lation prevalence of 0·004% for HBsAg (range −3·3%
to 6·2%, mean 0·6%) and −0·02% for anti-HCV
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Table 3. Simple estimates of the number of adults with hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) in WHO European Region
Population
aged515 yr
in 2008
Prevalence in ﬁrst
time blood donors
Prevalence in studies
representing general
population
Prevalence in general
population imputed
from blood donors* Prevalence estimate used
Estimated numbers
with infection
(rounded to nearest 100)
Country aged515 yr HBsAg Anti-HCV HBsAg Anti-HCV HBsAg Anti-HCV HBsAg Anti-HCV HBsAg Anti-HCV Chronic HCV
Those outside EU/EFTA
Albania 2389000 7·0% 0·7% 9·0% 3·0% 11% 2·5% Measured Measured 215000 71700 53000
Armenia 2431000
Azerbaijan 6549000
Belarus 8228000
Bosnia & Herzegovina 3170000 0·1% 0·03% 0·1% 0·1% Imputed from BD Imputed from BD 4700 1900 1400
Croatia 3760000 0·2% 0·1% 0·3% 0·2% Imputed from BD Imputed from BD 10200 7600 5600
Georgia 3575000 6·7% Measured 239500 177200
Israel 5077000 0·1% 0·1% 0·2% 0·2% Imputed from BD Imputed from BD 8300 10400 7700
Kazakhstan 11796000 1·8% 3·8% 1·0% 2·4% Measured Measured 448200 118000 87300
Kyrgyzstan 3790000 1·6% Measured 60600 44900
Montenegro 498000 0·7% 0·6% 1·0% 1·2% Imputed from BD Imputed from BD 5000 5900 4400
Republic of Moldova 3016000
Russian Federation 120185000 1·1% 2·1% 1·5% 3·6% 1·5% 4·3% Measured Measured 1802800 4326700 3201700
Serbia 8068000 4·2% 0·3% 2·4% 0·5% 5·7% 0·6% Measured Measured 193600 40300 29900
Tajikistan 4239000 3·0% 2·9% 0·5% 4·1% 5·9% Imputed from BD Measured 171800 21200 15700
FYR Macedonia 1674000 1·0% 0·2% 1·4% 0·5% Imputed from BD Imputed from BD 22800 7500 5600
Turkey 53958000 2·1% 0·3% 3·4% 0·7% 2·9% 0·7% Measured Measured 1834600 377700 279500
Turkmenistan 3531000
Ukraine 39554000 1·0% 1·3% 1·3% 12% 1·3% 2·7% Measured Measured 514200 4746500 3512400
Uzbekistan 19034000 5·2% 6·4% 13·3% 13·1% 7·1% 13% Measured Measured 2531500 2493500 1845200
Countries without HBsAg 31120000 3·4% Estimated from median prevalence 1058100
Anti-HCV 15527000 2·3% Estimated from median prevalence 357100 264300
Total (rounded to nearest 1000) 8821000 12886000 95360000
Those in EU/EFTA
Austria 7087000 0·1% 0·1% 0·3% 0·5% Imputed from BD Imputed from BD 24300 37900 28000
Belgium 8790000 0·1% 0·03% 0·7% 0·6% 0·4% 0·3% Measured Measured 61500 52700 39000
Bulgaria 6606000 1·8% 0·4% 1·3% 7·9% 4·5% Imputed from BD Measured 520800 85900 63500
Cyprus 707000 0·1% 0·02% 0·9% 0·4% 0·2% Measured Imputed from BD 6400 1400 1000
Czech Republic 8875000 0·04% 0·13% 0·6% 0·2% 1·3% Measured Imputed from BD 53300 118000 87300
Denmark 4476000 0·03% 0·03% 0·1% 0·3% Imputed from BD Imputed from BD 6100 12400 9200
Estonia 1140000 0·3% 0·7% 1·2% 7·0% Imputed from BD Imputed from BD 13600 79600 58900
Finland 4403000 0·03% 0·04% 0·2% 0·1% 0·4% Measured Imputed from BD 8800 17900 13200
France 50870000 0·03% 0·02% 1·3% 0·1% 0·2% Imputed from BD Measured 61400 661300 489400
Germany 70748000 0·1% 0·1% 0·6% 0·4% 0·6% 0·8% Measured Measured 424500 283000 209400
Greece 9578000 2·0% 0·3% 2·1% 1·0% 8·4% 3·3% Measured Measured 201100 95800 70900
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Table 3 (cont.)
Population
aged515 yr
in 2008
Prevalence in ﬁrst
time blood donors
Prevalence in studies
representing general
population
Prevalence in general
population imputed
from blood donors* Prevalence estimate used
Estimated numbers
with infection
(rounded to nearest 100)
Country aged515 yr HBsAg Anti-HCV HBsAg Anti-HCV HBsAg Anti-HCV HBsAg Anti-HCV HBsAg Anti-HCV Chronic HCV
Hungary 8511000 0·0% 0·3% 0·0% 3·1% Imputed from BD Imputed from BD 2600 267400 197900
Iceland 249000
Ireland 3506000 0·01% 0·01% 0·1% 0·1% 0·1% Measured Imputed from BD 3500 3100 2300
Italy 51260000 0·4% 1·4% 5·2% 1·7% Measured Measured 717600 2665500 1972500
Latvia 1943000
Lithuania 2823000 0·6% 1·0% 2·6% 10·3% Imputed from BD Imputed from BD 73900 289800 214500
Luxembourg 395000 0·1% 0·1% 0·4% 0·6% Imputed from BD Imputed from BD 1700 2500 1800
Malta 342000
Netherlands 13553000 0·1% 0·02% 0·1% 0·4% 0·3% 0·2% Measured Measured 13600 54200 40100
Norway 3862000 0·03% 0·03% 0·1% 0·4% Imputed from BD Imputed from BD 4400 13600 10000
Poland 32389000 0·5% 0·2% 1·9% 2·0% 1·9% Imputed from BD Measured 659800 615400 455400
Portugal 9076000 0·1% 0·2% 0·4% 1·7% Imputed from BD Imputed from BD 36900 157000 116100
Romania 18157000 3·7% 0·9% 5·6% 3·5% 15·8% 9·2% Measured Measured 1016800 635500 470300
Slovakia 4536000 0·1% 0·1% 0·6% 0·6% 0·5% Measured Imputed from BD 27200 24000 17700
Slovenia 1733000 0·1% 0·03% 0·4% 0·4% Imputed from BD Imputed from BD 7500 6100 4500
Spain 37814000 0·2% 0·1% 1·0% 2·0% 0·7% 1·4% Measured Measured 378100 756300 559600
Sweden 7641000 0·05% 0·1% 0·2% 0·4% 0·2% 0·6% Measured Measured 15300 30600 22600
Switzerland 6335000 0·2% 0·1% 0·7% 0·6% Imputed from BD Imputed from BD 44800 40600 30000
United Kingdom 50210000 0·04% 0·04% 0·7% 0·2% 0·4% Imputed from BD Measured 86400 351500 260100
Countries without HbsAg 2534000 0·6% Estimated from median prevalence 15200
Anti-HCV 2534000 1·2% Estimated from median prevalence 29100 21600
Total (rounded to nearest 1000) 4487000 7387900 5467000
Total Europe
732137000
13308000 20274000 15003000
1·8% 2·8% 2·0%
BD, Blood donors; FYR Macedonia, Former Yugoslav Republic of Macedonia; Anti-HCV, antibodies to the hpatitis C virus; EU/EFTA, European Union and European
Free Trade Association area.
* Estimated using median of the national ratios of the general population prevalence to prevalence in blood donors.
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(a) Prevalence in the general adult population
Hatched countries in maps are those outside the WHO Europeon Region. 
(b) Prevalence in people who inject drugs (PWID)
Legend
Anti-HCV prevalence
Legend
Anti-HCV prevalence PWID
Legend
HBsAg prevalence PWID
Legend
HBsAg prevalence
No data
1–5%
<1%
>5–10%
>10%
No data
20–50%
<20%
>50–70%
>70%
No data
1–5%
<1%
>5–10%
>10%
No data
1–5%
<1%
>5–10%
>10%
Fig. 1. Prevalence of antibodies to hepatitis C virus (anti-HCV) and hepatitis B surface antigen (HBsAg) in (a) the general adult population; (b) people who inject drugs
(PWID) in the WHO European region, by country. Hatched areas on maps indicate countries outside the WHO European Region.
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(range −5·4% to 9·3%, mean 0·7%). This variability
indicates that a country prevalence imputed this way
should be treated with caution.
Simple estimates of total numbers infected
The selected and imputed prevalences obtained here
were applied to population data to produce simple
estimates of the numbers infected. These estimates
indicate that of the 304·5 million adults living outside
the EU/EFTA area 8·8 million (2·9%) have HBsAg
and 9·5 million (3·1%) have HCV RNA (Table 3).
Comparable estimates for the EU/EFTA countries
obtained by applying the same method to published
data [7] (Table 3, Fig. 1; the median ratio between
the selected general population and the selected
blood-donor prevalence used in the imputations was
4·3 for HBsAg and 11 for anti-HCV). These indicated
that of the 427·6 million adults in the EU/EFTA
countries 4·5 million (1·0%) have HBsAg and
5·5 million (1·3%) have HCV RNA (Table 3). These
levels are respectively around one-third and one
half of the levels estimated for the area outside the
EU/EFTA. Combining these simple estimates in-
dicates that of the 732·1 million adults in the WHO
European Region 13·3 million (1·8%) have HBsAg
and 15·0 million (2·0%) have HCV RNA; with
two-thirds of those living with each infection outside
the EU/EFTA area (Table 4).
Simple estimates of total number of infected PWID
The selected and imputed estimates of prevalence in
PWIDwere used to derive simple estimates of the num-
ber of current PWID living with HBV and HCV infec-
tion outside the EU/EFTA. Considering thewide range
in the estimated prevalences of injecting drug use
(0·077–3·6%) and in the prevalences of the two infec-
tions in PWID (see above) the imputed data should
be viewed with great caution. These estimates indicate
that of the estimated 3·2 million current PWID outside
the EU/EFTA 0·7 million (21%) have HBsAg and
1·5 milion (47%) have HCV RNA (Table 5).
Comparable estimates for current PWID living in
EU/EFTA countries were derived from published
data [27] by applying the same method (Table 5,
Fig. 1). These estimates for EU/EFTA should be
viewed cautiously, as due to the substantial variability
in the prevalences (injecting drug use: 0·06–1·2%,
median 0·28%, mean 0·31%; HBsAg: 0·3–10%,
median 3·5%, mean 3·7%; anti-HCV: 12–88%, median
59%, mean 58%) the imputed data used here are likely
to be subject to much uncertainty. The estimation pro-
cess indicates that of the estimated 1·2 million current
PWID in the EU/EFTA area 45000 (3·7%) have
HBsAg and 0·5 million (43%) have HCV RNA
(Table 5). The proportion with anti-HCV is compar-
able with the level outside of the EU/EFTA; however,
the proportion with HBsAg is much lower (Table 4).
Combining these estimates indicates that in current
PWID (estimated 4·5 million) across the WHO
European Region 0·7 million (15%) have HBsAg
and 2·0 million (44%) have HCV RNA (Table 5).
DISCUSSION
Our simple estimates suggest that almost 1/50 adults
in the WHO European Region have HBV infection
and a similar proportion chronic HCV. Outside of
the EU/EFTA area prevalence was around three
times higher for HBsAg and over twice as high for
Table 4. Estimates of number of current hepatitis B and C infections in the WHO European Region: EU/EFTA
and non-EU/EFTA comparisons
Adult population (%) Current HBV (%) Current HCV (%)
EU/EFTA* 427615000 (58) 4487000 (34) 5467000 (36)
Non EU/EFTA† 304522000 (42) 8821000 (66) 9536000 (64)
WHO European Region 732137000 (100) 13308000 (100) 15003000 (100)
EU/EFTA, European Union and European Free Trade Association area.
* Twenty-seven EU Member States: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland,
France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland,
Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.
Four EEA/EFTA countries: Norway, Iceland, Liechtenstein, Switzerland.
†Albania, Armenia, Azerbaijan, Belarus, Bosnia & Herzegovina, Croatia, Georgia, Israel, Kazakhstan, Kyrgyzstan,
Montenegro, Republic of Moldova, Russian Federation, Serbia (incl. Kosovo), Tajikistan, The former Yugoslav Republic
of Macedonia, Turkey, Turkmenistan, Ukraine.
280 V. D. Hope and others
Table 5. Simple estimates of the number of people who inject drugs with hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) in
WHO European Region
Country
Population aged
515 yr in 2008
Estimated number of current PWID*
Prevalence
Estimated numbers with infection
(rounded to nearest 100)
Number Prevalence
Imputed from
median prevalence HBsAg Anti-HCV HBsAg Anti-HCV
Chronic
HCV
Those outside EU/EFTA
Albania 2389000 10000 15% 13% 1500 1300 900
Armenia 2431000 2000 0·08%
Azerbaijan 6549000 300000 4·58% 5·9% 54% 17700 162700 120400
Belarus 8228000 6308 0·08% 13% 39% 800 2500 1800
Bosnia and Herzegovina 3170000 5500 0·17% 2·7% 38% 100 2100 1500
Croatia 3760000 16740 0·45% 0·8% 46% 100 7700 5700
Georgia 3575000 127833 3·58% 2·9% 67% 3700 85600 63400
Israel 5077000 21000 4·3% 62% 900 13000 9600
Kazakhstan 11796000 100000 0·85% 7·9% 60% 7900 60000 44400
Kyrgyzstan 3790000 25000 0·66% 54% 13600 10000
Montenegro 498000 2000 38% 800 600
Republic of Moldova 3016000 3810 0·13% 6·8% 43% 300 1600 1200
Russian Federation 120185000 1825000 1·52% 31% 73% 565800 1332300 985900
Serbia 8068000 18000 0·22% 15% 52% 2600 9400 6900
Tajikistan 4239000 17000 0·40% 33% 5500 4100
FYR Macedonia 1674000 2691 0·16%
Turkey 53958000 226000 2·9% 5·3% 6600 12000 8900
Turkmenistan 3531000 14000
Ukraine 39554000 375000 0·95% 12% 71% 44000 266300 197000
Uzbekistan 19034000 80000 0·42% 36% 28800 21300
Median prevalence of injecting drug use 0·4%
Countries without HBsAg estimated
using median prevalence
142691 6·8% 9700
Countries without anti-HCV
estimated using median prevalence
18691 46% 8600 6400
Total (rounded to nearest 1000) 662000 2014000 1490000
Those in UE/EFTA
Austria2 7087000 17500 0·25% 53% 9300 6900
Belgium4 8790000 25800 0·29% 3·7% 74% 1000 19100 14100
Bulgaria5 6606000 20250 0·31% 5·5% 58% 1100 11700 8700
Cyprus1 707000 446 0·06% 3·5% 36% 20 200 100
Czech Republic1 8875000 31200 0·35% 12% 3700 2700
Denmark1 4476000 12754 0·28% 53% 6700 5000
Estonia4 1140000 13801 1·21% 90% 12400 9200
Finland3 4403000 15650 0·36% 42% 6600 4900
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Table 5 (cont.)
Country
Population aged
515 yr in 2008
Estimated number of current PWID*
Prevalence
Estimated numbers with infection
(rounded to nearest 100)
Number Prevalence
Imputed from
median prevalence HBsAg Anti-HCV HBsAg Anti-HCV
Chronic
HCV
France3 50870000 122000 0·24% 45% 54900 40600
Germany5 70748000 94250 0·13% 2·0% 75% 1900 70700 52300
Greece2 9578000 8148 0·09% 2·5% 50% 200 4100 3000
Hungary1 8511000 3941 0·05% 0·5% 23% 20 900 700
Iceland 249000 600
Ireland5 3506000 6289 0·18% 0·4% 72% 30 4500 3400
Italy1 51260000 326000 0·64% 59% 193000 142800
Latvia5 1943000 5500 74% 4100 3000
Lithuania4 2823000 5123 0·18% 5·9% 73% 300 3700 2800
Luxembourg1 395000 1482 0·38% 3·9% 81% 100 1200 900
Malta1 342000 900 33% 300 200
Netherlands4 13553000 3115 0·02% 3·0% 77% 100 2400 1800
Norway1 3862000 10032 0·26% 1·2% 74% 100 7400 5500
Poland4 32389000 88000 4·6% 59% 4000 51900 38400
Portugal2 9076000 16425 0·18% 5·0% 46% 800 7600 5600
Romania5 18157000 49000 10% 64% 5000 31400 23200
Slovakia5 4536000 18841 0·42% 50% 9400 7000
Slovenia1 1733000 7310 0·42% 3·4% 22% 200 1600 1200
Spain3 37814000 83972 0·22% 73% 61600 45500
Sweden5 7641000 29513 0·39% 88% 26000 19300
Switzerland1 6335000 31653 0·50% 78% 24700 18300
United Kingdom4 50210000 142650 0·28% 46% 65600 48600
Median prevalence of injecting drug use 0·3%
Countries without HBsAg estimated
using median prevalence
852534 3·5% 29800
Countries without anti-HCV estimated
using median prevalence
600 59% 400 300
Total (rounded to nearest 1000) 45000 697000 516000
Total Europe (rounded to nearest 1000) 706000 2711000 2006000
FYR, The Former Yugoslav Republic of Macedonia; Anti-HCV, antibodies to the hepatitis C virus; EU/EFTA, European Union and European Free Trade Association area;
EU/EFTA HBsAg and anti-HCV data from EMCDDA website plus a literature search for Switzerland and Iceland (1 National study; 2 weighted mean of national studies;
3 multi-city; 4 weighted mean from city/sub-region studies; 5 one city/region.)
*Mathers et al. [26], plus data for Bosnia & Herzegovina, Croatia, Czech Republic, Cyprus, Estonia, Greece, Luxembourg, Macedonia, Portugal, Sweden, and United
Kingdom from EMCDDA website; and data for Serbia from the Republic of Serbia UNGASS Country Progress Report on AIDS 2010.
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HCV RNA. Prevalence of these infections was highest
in PWID (15% and 44%, respectively). Although the
estimates here need to be viewed with caution, they
do suggest a sizable burden due to these two viral
infections in the Region, particularly outside the
EU/EFTA area.
First, it is important to consider the limitations
of this study. The prevalence data on HBsAg and
anti-HCV were obtained from literature searches,
while grey literature was included, it is possible
studies will still have been missed particularly if
they have recently been undertaken, reported in
languages other than Russian or English, or un-
published. Second, measures of the prevalence of
HBsAg and anti-HCV were not identiﬁed in all
populations or in all countries. In many countries
no national studies had been undertaken, thus local
and regional data were assumed to be reﬂective of
the whole country. Small studies (n<100) and those
where population was not speciﬁcally or clearly
deﬁned were excluded; however, we did not asses
the methodological quality of the studies, in part
because data available was often limited. The studies
used a range of designs and thus the robustness of the
resulting data is likely to be variable. Where no
measure of prevalence was found, simple imputation
approaches were applied. Considering these limit-
ations it is important that the ﬁndings are viewed
cautiously. Even so, the extensive nature of searches
undertaken in this assessment mean that it is likely
to provide as robust an estimation as is currently
practical at the regional level.
In the WHO European Region outside the EU/
EFTA, the measured HBsAg and anti-HCV preva-
lences were highest in PWID, but infection was also
common in the general population (3·8% and 2·3%,
respectively), MSM (8·7% and 4·2%, respectively),
and in sex workers (3·3% and 11%, respectively).
There was substantial variation between countries,
while prevalence of these infections in PWID was
high in most countries; Uzbekistan had a prevalence
of 13% for both infections in the general population.
The general population HCV prevalence estimate
was also elevated in the Ukraine and Georgia, and
in Albania the general population HBsAg prevalence
estimate was elevated. While these differences might
be related to the methodologies used in the studies,
they warrant further investigation.
For the general population, PWID and MSM
prevalences were higher than in the EU/EFTA area
[7], although comparable data for EU/EFTA was
very limited for MSM. The ECDC review [7] found
only two studies from the EU/EFTA countries that
had measured HBsAg in MSM [4% Sweden
1993–1997, and <1% UK (Scotland) 1993–2003] and
one study that had measured anti-HCV [1·3%
Amsterdam (The Netherlands) 2003], indicating a
need for further studies of prevalence for MSM and
other transmission risk populations. For sex workers
data on the prevalence of these infections has not
been reviewed for the EU/EFTA area, but considering
the elevated prevalence found here this is needed.
In the countries outside the EU/EFTA, MSM have
a higher prevalence of both HBsAg and anti-
HCV than the general population, and sex workers
had higher anti-HCV prevalence. The high anti-
HCV prevalence in MSM and sex workers possibly
reﬂects an overlap with the PWID population
[8]. The higher prevalences of both infections in
MSM is a concern considering the evolving epidemic
of HIV in this group in parts of central and eastern
Europe [28].
The ratios between the general population estimates
and the blood-donor estimates were higher for the
EU/EFTA area compared to outside (almost three
times higher for HBsAg and about ﬁve times higher
for anti-HCV). The reasons for this difference are
unclear, but it could for example, be due to more
success in excluding those who have been at risk of
infection from blood donation in the EU/EFTA
countries, or be a reﬂection of the higher prevalence
of these infections in the general population outside
the EU/EFTA area. This difference needs further
investigation.
The estimates of the numbers infected simply
applied prevalence to population data; with the preva-
lences derived from studies using a range of method-
ologies and imputed for countries with no data
(the majority lacked a general population HBsAg
estimate). There is some corroboration for the esti-
mates obtained from comparison with published
national estimates for HCV. In Italy a modelling
approach estimated 2·1 million people chronically
infected with HCV in 2000 and 1·9 million in 2005
[29] compared to the 2·0 million estimated here. In
the UK, modelling approaches suggest that around
200000 people are living with chronic HCV infec-
tion [30, 31], while the simple UK estimate here
(n=260100) is higher it is within the conﬁdence range.
For the PWID estimates there is some corrobor-
ation from the UK, where 66000 current PWID
were estimated as HCV-infected in England and
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Wales [30] compared to the simple UK estimate here
of 48600 – though the study had estimated a larger
injecting population than the one used here. The esti-
mates of the number of infected PWID obtained here
will be particularly uncertain, as estimates of infection
prevalence are being simply applied to estimates of the
number of current PWID. Both of these are difﬁcult to
measure due to the illicit and marginalized nature of
injecting drug use, and are thus are likely to be subject
to much uncertainty. The estimated number of PWID
should thus be used very cautiously. In the UK almost
as many former PWID were estimated to have HCV
as current PWID [30]. The estimates obtained here
relate to number of infected current PWID, but
there will also be many former PWID that will have
been infected. It is thus likely that many of the infec-
tions in the region not in current PWID will be in for-
mer PWID.
A previous estimate had suggested that 14 million
people were living with chronic HBV [32] in the
WHO European Region, although the method used
for this estimate is not given, it provides some cor-
roboration for the 13·3 million estimated here. In the
1990s, it was estimated from national prevalence data,
that there were 8·9 million people living with HCV [4]
in the WHO European Region (prevalence 1·0%), our
estimate suggest that HCV infection might have
increased over time to 15 million (prevalence 2·0%). If
so, this might reﬂect transmission in PWID, particu-
larly in the east of the Region, where there has been a
recent and accelerating epidemic of HIV in PWID [33].
Viral hepatitis has been recognized as a global pub-
lic health problem and a World Health Assembly
Resolution [34] has called on Member States to take
action to strengthen preventive and control measures.
Our ﬁndings indicate a large pool of individuals
infected with HBV and HCV in the WHO European
Region, and so the potential for further transmission.
The WHO’s recent Framework for Global Action to
prevent and control viral hepatitis [1] describes the
work needed. Interventions to prevent transmission
[2, 9, 35], including information on safer sex, condom
distribution, needle and syringe programmes, and
strict infection control practices in healthcare and
other settings, need to be maintained and expanded
as appropriate. HBV can be prevented through vacci-
nation, national policies should be reviewed regularly,
and in those countries with universal vaccination
programmes targeted vaccination of high-risk groups
should be considered, as recommended by WHO
[36]. Both HBV and HCV can, to varying degrees,
be successfully treated. Easy access to diagnostic test-
ing is an important entry point for accessing both
prevention and treatment programmes, and in higher
prevalence countries targeted screening programmes
should be considered for those at greatest risk. Other
measures can also reduce the transmission of viral
hepatitis, such as, ensuring a safe blood supply.
This study provides useful data for policy makers
on the scale of HBV and HCV infection in the region.
Policy makers need consider the extent of these dis-
eases when planning health services in order to ensure
that appropriate interventions [35–37] are provided on
a sufﬁcient scale to reduce the burden arising from
these two preventable infections.
These ﬁndings indicate that there may be over
13 million adults living with HBV and 15 million
with HCV in the WHO European Region – indicating
a large burden for treatment and care. The prevalence
of these infections appears to be higher outside the
EU/EFTA, with these countries (mainly in eastern
Europe and central Asia) accounting for 66% of
those with HBsAg and 64% of those with HCV
RNA, yet only 42% of the European Region’s adult
population (Table 4). Efforts to prevent, diagnose
and treat these infections need to be maintained and
improved. Surveillance of the seroprevalence of these
infections and related risk behaviours in the affected
populations is needed to monitor trends and allow
assessment of the impact of interventions.
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